– Reuters
Oppenheimer Downgrades Snap to Perform
Oppenheimer analyst Jason Helfstein downgrades Snap (NYSE:SNAP) from Outperform to Perform.
Related Posts
H.B. Fuller Sees Q4 2022 Adj. EPS $1.15-$1.30 Vs $1.28 Est; Sees Net Interest Expense For FY22 $80M-$85M
Fiscal 2022 Outlook:
Company is increasing full-year expectations for adjusted EBITDA, despite slower economic conditions, stronger U.S. Dollar, and continued raw material cost inflation;
Organic revenue growth
HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $24
HC Wainwright & Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $18 to $24.
UBS Maintains Buy on Plains All American, Raises Price Target to $17
UBS analyst Joseph Parkhill maintains Plains All American (NASDAQ:PAA) with a Buy and raises the price target from $16 to $17.